Blood cancer treatment showdown: two drug combo vs. single therapy
NCT ID NCT07318662
Summary
This study is looking at which treatment works better for people with higher-risk forms of two blood disorders called MDS and CMML. Researchers are comparing a two-drug combination (venetoclax plus HMAs) against just the HMAs drug alone. They're reviewing medical records of 224 patients to see which approach gives better results with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.